q3 adjusted earnings per share $69.00.
q1 sales $426 million versus refinitiv ibes estimate of $426.5 million.
qtrly net sales $11.7 million versus refinitiv ibes estimate of $12.3 million.
qtrly sales fell 23% to $11.7 million.
qtrly adjusted eva da decreased by approximately $6.5 million.
sees fy 2021 total revenue $106 million to $110 million.
q1 earnings per share $12.0.
q1 sales fell 20 percent to $1.4 billion.
expect long-term consumption growth to continue between 1% and 2% per year.
compname reports second quarter 2021 results and announces 2.5x target leverage ratio.
compname reports third quarter 2021 results, announces 30% increase in common stock dividend and raises full-year guidance.
revised its 2021 capital expenditures guidance from 60 to 65 million to 55 to 16 million.
qtrly tissue demand is expected to weaken further from q1 shipments of 11 point 7 million cases as our shipments in april are at 3.1 million cases compared to a monthly average of 3.9 million cases in q1 of 2021.
q2 production is expected to exceed 1/3 of our peak demonstrated production of 15 point 9 million cases in q2 of 2020.
sees fy 2021 adjusted earnings per share $68 to $3536.
qtrly net sales of $1.6 billion, up 6% from a year ago.
